BACKGROUND: Preexposure prophylaxis (PrEP) could protect individuals engaging in repeated high-risk behaviors from HIV infection. Understanding the demographic and behavioral predictors of intent-to-use PrEP may prove useful to identify clinical trial participants. METHODS: In 2007, 227 HIV-uninfected men who report having sex with men (MSM) recruited through modified respondent-driven sampling completed an interviewer-administered survey assessing prior PrEP use and awareness, future intent-to-use PrEP, demographics, sexual risk, psychosocial variables, and drug/alcohol use. Bivariate and multivariable logistic regression procedures examined predictors of intent-to-use PrEP. RESULTS: Mean age of participants was 41 (SD = 9.1); 54% were nonwhite. One participant reported prior off-label PrEP use (medication obtained from his HIV-infected brother). Nineteen percent had previously heard of PrEP, whereas 74% reported intent-to-use PrEP if available after being educated about its potential. In multivariable analysis controlling for age and race/ethnicity, significant predictors of intent-to-use PrEP included the following: less education [odds ratio (OR) = 7.7; P = 0.04], moderate income (OR = 13.0; P = 0.04), no perceived side effects from taking PrEP (OR = 3.5; P = 0.001), and not having to pay for PrEP (OR = 4.2; P = 0.05). DISCUSSION: Many New England MSM indicated an interest in using PrEP after learning about its potential, particularly if they could obtain PrEP at no expense and if PrEP had no side effects. Less educated MSM and those who knew less about PrEP and antiretroviral therapy before entering the study were more open to using antiretroviral therapy for prevention once they had received some information suggesting its potential value. Findings suggest that careful educational messages are necessary to ensure appropriate PrEP use if clinical trials reveal partial efficacy.
BACKGROUND: Preexposure prophylaxis (PrEP) could protect individuals engaging in repeated high-risk behaviors from HIV infection. Understanding the demographic and behavioral predictors of intent-to-use PrEP may prove useful to identify clinical trial participants. METHODS: In 2007, 227 HIV-uninfectedmen who report having sex with men (MSM) recruited through modified respondent-driven sampling completed an interviewer-administered survey assessing prior PrEP use and awareness, future intent-to-use PrEP, demographics, sexual risk, psychosocial variables, and drug/alcohol use. Bivariate and multivariable logistic regression procedures examined predictors of intent-to-use PrEP. RESULTS: Mean age of participants was 41 (SD = 9.1); 54% were nonwhite. One participant reported prior off-label PrEP use (medication obtained from his HIV-infected brother). Nineteen percent had previously heard of PrEP, whereas 74% reported intent-to-use PrEP if available after being educated about its potential. In multivariable analysis controlling for age and race/ethnicity, significant predictors of intent-to-use PrEP included the following: less education [odds ratio (OR) = 7.7; P = 0.04], moderate income (OR = 13.0; P = 0.04), no perceived side effects from taking PrEP (OR = 3.5; P = 0.001), and not having to pay for PrEP (OR = 4.2; P = 0.05). DISCUSSION: Many New England MSM indicated an interest in using PrEP after learning about its potential, particularly if they could obtain PrEP at no expense and if PrEP had no side effects. Less educated MSM and those who knew less about PrEP and antiretroviral therapy before entering the study were more open to using antiretroviral therapy for prevention once they had received some information suggesting its potential value. Findings suggest that careful educational messages are necessary to ensure appropriate PrEP use if clinical trials reveal partial efficacy.
Authors: Albert Y Liu; Pravina V Kittredge; Eric Vittinghoff; H Fisher Raymond; Katherine Ahrens; Tim Matheson; Jennifer Hecht; Jeffrey D Klausner; Susan P Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2008-02-01 Impact factor: 3.731
Authors: D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell Journal: N Engl J Med Date: 1997-11-20 Impact factor: 91.245
Authors: Mauro Schechter; Regina F do Lago; Aaron B Mendelsohn; Ronaldo I Moreira; Lawrence H Moulton; Lee H Harrison Journal: J Acquir Immune Defic Syndr Date: 2004-04-15 Impact factor: 3.731
Authors: Ronald A Brooks; Raphael J Landovitz; Rachel L Kaplan; Eli Lieber; Sung-Jae Lee; Thomas W Barkley Journal: AIDS Patient Care STDS Date: 2011-12-07 Impact factor: 5.078
Authors: Matthew J Mimiaga; Sari L Reisner; Yves-Michel Fontaine; Sean E Bland; Maura A Driscoll; Deborah Isenberg; Kevin Cranston; Margie R Skeer; Kenneth H Mayer Journal: Drug Alcohol Depend Date: 2010-03-23 Impact factor: 4.492
Authors: Hailey J Gilmore; Albert Liu; Kimberly Ann Koester; K Rivet Amico; Vanessa McMahan; Pedro Goicochea; Lorena Vargas; David Lubensky; Susan Buchbinder; Robert Grant Journal: AIDS Patient Care STDS Date: 2013-10 Impact factor: 5.078